Virus-like particles (VLPs) are protein-based structures that mimic viruses and bind to antibodies. Because VLPs are not infectious, they show considerable promise as vaccine platforms for many viral diseases, including influenza. Realizing that fine details about influenza VLPs were scant, ... more
Scientists work toward a rapid point-of-care diagnostic test for Lyme disease
A study published in the Journal of Clinical Microbiology describes a new rapid assay for Lyme disease that could lead to a practical test for use by healthcare providers. The researchers found the assay, which uses several biomarkers to detect Lyme disease infection, was more sensitive than current laboratory-based tests when diagnosing Lyme disease early after suspected infection. The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Lyme disease is caused by Borrelia burgdorferi, a spiral-shaped bacterium transmitted by deer ticks. Most cases of Lyme disease can be treated effectively with a short course of antibiotics. However, Lyme disease can be difficult to diagnose because it causes a wide range of symptoms, from fever and rash to neurologic and cardiac symptoms and joint pain. Current Lyme disease tests also can miss an infection if performed too early. The Centers for Disease Control and Prevention recommends a two-step blood test for diagnosing Lyme disease that looks for antibodies against Lyme disease. These tests require specialized laboratory equipment and can require days or weeks to return results. The authors of the paper plan to develop a simpler, faster, more sensitive test that could be used at the point of care during a single visit to a healthcare provider.
The researchers first screened a set of known Lyme disease biomarkers for their ability to indicate infection. They then tested for the top three biomarkers on samples from people with early Lyme disease, from healthy individuals from areas where Lyme disease is endemic, and from people with Lyme arthritis. This was compared to results obtained using the standard two-step testing procedure.
Overall, the new set of biomarkers was more sensitive than standard Lyme disease tests. These biomarkers were better at picking up signs of Lyme disease infection in early stage samples--possibly because they were able to detect antibodies that peak in the first two to six weeks after a person is infected with Lyme disease. These results open the possibility of developing a point-of-care test for Lyme disease. While the assay will require more refinement and testing before it can be approved by the Food and Drug Administration for widespread use as a simple diagnostic test for Lyme disease, the researchers say that these results show great potential.
- Lyme disease
- point-of-care diagnosis
- rapid tests
- Borrelia burgdorferi
Losing just one night of sleep led to an immediate increase in beta-amyloid, a protein in the brain associated with Alzheimer's disease, according to a small, new study by researchers at the National Institutes of Health. In Alzheimer's disease, beta-amyloid proteins clump together to form ... more
The first three-dimensional structure of DHHC proteins--enzymes involved in many cellular processes, including cancer--explains how they function and may offer a blueprint for designing therapeutic drugs. Researchers have proposed blocking DHHC activity to boost the effectiveness of first-l ... more
Using a simple "mirror trick" and not-so-simple computational analysis, scientists affiliated with the Marine Biological Laboratory (MBL) have considerably improved the speed, efficiency, and resolution of a light-sheet microscope, with broad applications for enhanced imaging of live cells ... more
- 1Virtual screening for active substances against the coronavirus
- 2analytica 2020 is postponed
- 3Thermo Fisher Scientific to Acquire QIAGEN
- 4FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
- 5The digital laboratory live and tangible
- 6Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization
- 7Smartphone lab finds coronavirus in saliva
- 8Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus
- 9Pool testing of SARS-CoV-02 samples increases worldwide test capacities many times over
- 10New membrane separates small organic molecules
- New blood test detects wide range of cancers
- Staining Cycles with Black Holes
- FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
- New device quickly detects harmful bacteria in blood
- Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus